The Silence After the Storm: Ro's New Scale Tackles the Relentless 'Food Noise'

The Long Road to Hope: Anavex's Alzheimer's Drug Hits a Regulatory Wall

Beyond the Pandemic: Moderna's Ambitious Bet on mRNA as the Next Big Cancer Weapon

A Major Setback: Moderna's Highly Anticipated CMV Vaccine Fails Key Efficacy Goal in Phase 3

The Rx Revolution: How Startups Are Rewriting the Rules of Drug Affordability

Another Heartbreak in the Fight Against Dementia: Alector's Flagship Drug Fails Late-Stage Trial

The Dawn of a New Era: How cT-DNA Blood Tests Are Transforming Cancer Surveillance

Gilead Halts HIV Drug Price Hikes Amidst Growing Scrutiny and Public Pressure

The AMA's Bold Stance: Navigating the Future of AI Regulation in Medicine

Beyond Vaccines: Moderna Co-Founder Warns of Widespread Attacks on Science

A Landmark Clash: India's Supreme Court Navigates Life-Saving SMA Drugs, Patents, and Public Access

A New Dawn for Early Breast Cancer: Enhertu's Groundbreaking Impact Revealed at ESMO 2025

A New Dawn for Breast Cancer Treatment: Roche's Gedatolisib and Giredestrant Combination Shows Promise

FDA Unleashes Game-Changing Incentive: Priority Review Vouchers Set to Revolutionize Drug Development

The Revolving Door: Ex-FDA Regulators Find New Homes at Pharma Giants Like Eli Lilly

A Looming Crisis: Funding Cuts Threaten Revolutionary Cancer Immunotherapy Breakthroughs

North Carolina's Biotech Boom: Powering the Future of Medicine Through Advanced Manufacturing

The Dawn of Precision: How Biomarkers are Revolutionizing Dementia Diagnosis

The Production Predicament: How Manufacturing Woes Threaten Novo Nordisk's Blockbuster Drugs

AI to the Rescue? Mass General Brigham's Bold Plan to Combat the Primary Care Doctor Shortage

Unlocking Tomorrow's Cures: Bristol Myers Squibb's Daring Dive into Next-Gen Autoimmune Cell Therapies

Boston-Cambridge: The Unrivaled Epicenter of Global Biotech Innovation

Monopar's Breakthrough in Wilson Disease: A New Dawn with AstraZeneca's Shadow

Biohaven's Breakthrough Bid: Navigating FDA Flexibility for Spinocerebellar Ataxia's Future

The Silent Revolution: AI Scribes Are Listening—Are We Ready for the Ethical Echoes?

The High-Stakes Battle Over Elevidys: Efficacy, Ethics, and the Future of Rare Disease Drugs

A New Chapter: Peter Marks, Former FDA Vaccine Czar, Lands at Eli Lilly

A Dark Day for Science: HHS Dismantles Crucial Bioethics and Science Advisory Boards

The Telehealth Tsunami: Unlocking Healthcare's Future with 50-State Doctor Licensing

The Great Pharmaceutical Reversal: Onshoring's Costly Gamble with Drug Affordability

Europe's Bold New Pharma Gambit: A High-Stakes Bet on Access Over Profit?

The Alarming Pivot: How Telehealth Giants Are Trading Patient Access for Pharmaceutical Profits

Unlocking Autism's Enigma: NIH Launches Groundbreaking Data Science Initiative with a Focus on Exposomics

Crucial Medicare Drug Price Loophole Fix Stalled: A Setback for Patient Savings

Biotech's Q4 Reckoning: Navigating the Storm, Charting the Future

Unveiling the Maternal Research Gap: Why Pregnant Women Need to Be Included in Clinical Trials

The Pharmaceutical Tsunami: How a Second Trump Term Could Reshape Drug Pricing, Medicare, and Vaccines

Healthcare's Brink: How a Government Shutdown Threatens HHS, CDC, and FDA

The Mind Behind Miracles: Daniel Skovronsky's Blueprint for Eli Lilly's R&D Revolution